Evaluation of antibody and T Cell immunity response in different immunization groups of inactive and mRNA COVID-19 vaccines.

Autor: Zerey Albayrak M; Republic of Turkey Ministry of Health, General Directorate of Public Health, Department of Microbiology Reference Laboratories and Biological Products, Ankara, Turkey. Electronic address: mzerey90@hotmail.com., Gül Yurtsever S; Izmir Katip Celebi University, Faculty of Medicine, Department of Microbiology, Izmir, Turkey., Peker BO; Atatürk Training and Research Hospital, Medical Microbiology Laboratory, Izmir, Turkey., Müderris T; Izmir Katip Celebi University, Faculty of Medicine, Department of Microbiology, Izmir, Turkey., Kaya S; Izmir Katip Celebi University, Faculty of Medicine, Department of Microbiology, Izmir, Turkey.
Jazyk: angličtina
Zdroj: Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2024 Jan; Vol. 108 (1), pp. 116122. Date of Electronic Publication: 2023 Oct 27.
DOI: 10.1016/j.diagmicrobio.2023.116122
Abstrakt: This study aimed to evaluate the antibody and T cell responses of homologous and heterologous booster doses for SARS-CoV-2 vaccines. Our study was performed on those with two doses of mRNA vaccine BNT162b2 (2B, n:44), those with heterologous booster dose BNT162b2 vaccine after two doses of inactivated vaccine CoronaVac (2S+1B, n:44), those with homologous booster dose vaccine CoronaVac after two doses of vaccine CoronaVac (3S, n:44) SARS-CoV-2 IgG antibody levels were significantly higher in individuals who received heterologous boosters(p<0.001). IFN-Ɣ, IL-2 and IL-13 median values were detected higher in 2S+1B group than in 3S group, respectively (p=0.112, p=0.057, p=0.341). Although the antibody levels in 2S+1B group were similar (p=0.153) to the 2B group; IFN-Ɣ, IL-2 and IL-13 levels were higher (p<0.001). In conclusion, supplementing an improved strategy based on inactivated vaccines with an mRNA vaccine as a heterologous booster is likely to be more beneficial in the course of the pandemic.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: